Branded Generics Market by Product, Drug Type, Route of Administration, Indication, Distribution Channel

Description

List of Tables

[194 Pages Report] The Branded Generics Market size was estimated at USD 432.30 billion in 2023 and expected to reach USD 494.29 billion in 2024, at a CAGR 14.66% to reach USD 1,126.43 billion by 2030.

Branded generic drugs refer to medications that are bioequivalent to the original innovator drug and are distributed under a different brand name by another company after patent expiration. These drugs are formulated using the same active pharmaceutical ingredients (APIs) as the innovator product and must meet similar regulatory requirements for manufacturing processes, safety profiles, and efficacy standards. However, branded generics may exhibit subtle differences in terms of excipients, packaging materials, or manufacturing techniques compared to their innovator counterparts. Increasing consumer awareness about accessible treatment options, rising healthcare expenditure, and increasing patent expirations on blockbuster drugs drive the growth of the branded generics market. However, stringent regulatory requirements for drug approval and quality control and price erosion resulting from intense competition among manufacturers may hinder market growth. Nevertheless, advancements in pharmaceutical research enabling the development of bioequivalent products create lucrative opportunities for the growth of the branded generics market.

KEY MARKET STATISTICS
Base Year [2023]	USD 432.30 billion
Estimated Year [2024]	USD 494.29 billion
Forecast Year [2030]	USD 1,126.43 billion
CAGR (%)	14.66%

Product: Significant adoption of value-added branded generics due to their additional advantages

Ttrade-named generics are the pharmaceutical product that combines the trusted efficacy of an established generic drug with the recognition and reputation of a well-known brand name. These products offer the benefits of both generic and branded medicines, with high quality at an affordable price. Pharmaceutical manufacturers commonly use trade-named generics to penetrate competitive markets, providing patients and healthcare professionals with cost-effective alternatives that maintain trust in safety, effectiveness, and reliability. Value-added offerings represent a distinct category that differentiates itself from standard formulations by bringing additional benefits to the consumer. These value-added products may combine multiple active ingredients for enhanced therapeutic effects or adopt innovative dosage forms for improved convenience, such as extended-release formulations or easy-to-swallow tablets. In some cases, value-added trade-named generics can also include drugs reformulated to reduce side effects or improve patient adherence, such as Benitek A (Olmesatran in combination with Amlodipine), Nifedical (nifedipine), and Digitek (digoxin).

Drug Type: High usage of anti-hypertensive for treating high blood pressure

Alkylating agents are a class of drugs primarily used in cancer treatment, and they work by inhibiting DNA replication restricting the growth and multiplication of cancer cells, such as cyclophosphamide, melphalan, and cisplatin. Anti-depressant medications are used to treat various forms of depression and anxiety disorders as they restore the balance of neurotransmitters within the brain, particularly serotonin, norepinephrine, and dopamine, and commonly prescribed anti-depressants include fluoxetine, venlafaxine, and amitriptyline. Anti-epileptic drugs (AEDs) are medications designed to prevent or control epileptic seizures in individuals diagnosed with epilepsy. Anti-hypertensive medications lower blood pressure in individuals with hypertension, reducing the risk of heart disease, stroke, and other complications. Antipsychotic medications are primarily used to manage symptoms of psychotic diseases such as bipolar disorder and schizophrenia. Antimetabolites are a group of chemotherapeutic agents that interfere with cellular metabolism and DNA synthesis in cancer cells while they mimic essential building blocks for DNA replication or inhibit critical enzymes involved in these processes. Hormone-based medications are used in various medical conditions, including hormone imbalances, endocrine disorders, and certain cancers. Lipid-lowering medications are designed to reduce elevated levels of triglyceride and cholesterol in the blood, lowering the chance of cardiovascular disorders such as heart attacks.

Route of Administration: Wide adoption of oral route due to their longer duration of action

The oral route is the most common and preferred method of drug administration due to its convenience, ease of use, and non-invasive nature. Branded generic medications in forms such as tablets, capsules, or liquids are taken orally by the patient. Additionally, they provide higher patient compliance as they do not require specialized equipment or healthcare professional oversight for administration. Parenteral administration involves delivering drugs directly into the bloodstream through means that bypass the digestive system. This route includes subcutaneous (SC), intramuscular (IM), and intravenous (IV) injections and infusions. This route is particularly beneficial when treating conditions requiring quick relief or if a drug has poor oral bioavailability. Additionally, it is generally more expensive than oral administration due to specialized equipment and sterile preparation requirements. Topical administration involves applying branded generic medications directly onto the skin or mucosal surfaces, such as creams, gels, ointments, or transdermal patches. This route allows localized drug delivery to the target site while minimizing systemic absorption and potential side effects. Advantages of topical administration include reduced risk of adverse reactions compared to systemic routes and improved patient compliance due to ease of use. However, challenges associated with topical drug delivery include variability in drug penetration through the skin barrier and the potential for irritation at the application site.

Indication: Burgeoning utilization of branded generics for gastrointestinal diseases and neurological diseases

Branded generics are crucial in providing options for analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), and opioids. Branded generics offer cost-effective alternatives for cardiovascular diseases such as managing hypertension, hyperlipidemia, heart failure, and arrhythmias. Skin conditions such as acne, fungal infections, eczema, and psoriasis are widespread concerns among patients globally, and branded generics provide affordable access to dermatological treatments, including corticosteroids, retinoids, and antifungal agents. Gastrointestinal diseases such as inflammatory bowel disease (IBD), gastroesophageal reflux disease (GERD), and irritable bowel syndrome (IBS) require long-term management with medications that are fulfilled by branded generics that offer cost-effective therapies, including proton-pump inhibitors (PPIs), H2 receptor antagonists, and antispasmodics. Neurological disorders such as epilepsy, Parkinson's disease, multiple sclerosis, and migraines demand effective treatments at affordable prices, and branded generics help bridge this gap with anti-epileptic drugs (AEDs), dopaminergic agents, and monoclonal antibodies. Branded generics provide cost-effective alternatives for chemotherapy drugs, hormone therapies, immunotherapies, and tyrosine kinase inhibitors (TKIs) for cancer treatment, as they are perceived as unattainable due to the high costs associated with innovative therapies and targeted agents. Generic versions of Celebrex (celecoxib) capsules, Vascepa (icosapent ethyl) capsules, Jublia (efinaconazole) topical solution, Asacol HD (mesalamine) tablets, Abraxane (nab-paclitaxel), Ampyra (dalfampridine) extended-release tablets are available for treating several diseases.

Distribution Channel: Evolving online distribution channels for branded generics

The offline distribution channel for branded generics remains the first preference for patients seeking medications, primarily due to ease of access and real-time consultation with healthcare professionals. Hospital pharmacies play a vital role in providing quality healthcare by ensuring patients have access to affordable medications during treatment. Hospital pharmacies increasingly favor branded generics as they balance affordability and quality assurance. These drugs are manufactured following strict guidelines and maintain a high efficacy comparable to their patented counterparts. Retail pharmacies serve as a primary source of medications among the general public and create an enormous potential for branded generics as consumers seek cost-effective alternatives without compromising on quality or efficacy. The rapid advancement of digital technologies has paved the way for online pharmacies and eCommerce platforms to emerge as significant players in the pharmaceutical distribution landscape. Branded generics have observed substantial growth in this space due to the convenience and cost savings these online channels provide due to its accessibility of detailed product information, competitive pricing, and reliable delivery services that have led consumers to prefer purchasing their medications online.

Regional Insights

In the Americas region, the branded generics market has a lucrative landscape due to its robust healthcare infrastructure and high per capita spending on pharmaceuticals. The government's initiatives to increase awareness about generic drugs have led to promising growth prospects for branded generics. Additionally, the investment in R&D by leading pharmaceutical companies has resulted in new product approvals and innovative therapeutics entering this market space. The European Union showcases a diverse landscape within the branded generics sector. There is considerable demand for cost-effective treatment options with increasing healthcare expenditure across EU countries and favorable pricing policies for generic medicines by national governments. Major players are investing heavily in research activities to develop novel drugs while maintaining competitiveness against low-cost alternatives from emerging markets. The Middle East and Africa offer notable potential for growth in the branded generics market as the government initiatives aimed at improving healthcare infrastructure and affordability of medicines are driving factors contributing to expanding market opportunities. The Asia-Pacific showcases immense potential for branded generics development owing to the rising research and development, supportive government initiatives, increasing demand for trade generics, and surging collaborations among international players to develop innovative therapies catering to global needs.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Branded Generics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Branded Generics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Branded Generics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Ajanta Pharma Ltd., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Apotex Inc., Aspen Pharmacare Holdings Limited, AstraZeneca PLC, Aurobindo Pharma Limited, Bausch Health Companies Inc., Bristol-Myers Squibb Company, Cipla Limited, Dr. Reddy's Laboratories Ltd., Endo International PLC, Eris Lifesciences Limited, Eva Pharma, Fresenius Kabi AG, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Hetero Drugs Limited, Lupin Limited, Micro Labs Limited, Nichi-Iko Pharmaceutical Co., Ltd., Pfizer Inc., Sandoz International GmbH by Novartis AG, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Viatris Inc., and Zentiva Group, a.s..

Market Segmentation & Coverage

This research report categorizes the Branded Generics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- Trade Named Generics
- Value-Added

Drug Type
- Alkylating Agents
- Anti-depressants
- Anti-epileptics
- Anti-hypertensive
- Anti-psychotics
- Antimetabolites
- Hormones
- Lipid Lowering Drugs

Route of Administration
- Oral
- Parenteral
- Topical

Indication
- Acute & Chronic Pain
- Cardiovascular Diseases
- Dermatological Diseases
- Gastrointestinal Diseases
- Neurological Diseases
- Oncology

Distribution Channel
- Offline
  - Hospital Pharmacy
  - Retail Pharmacy

Online

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Branded Generics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Branded Generics Market?

3. What are the technology trends and regulatory frameworks in the Branded Generics Market?

4. What is the market share of the leading vendors in the Branded Generics Market?

5. Which modes and strategic moves are suitable for entering the Branded Generics Market?

Product Code: MRR-A26E0E57422E

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Prevalence of chronic diseases necessitating the use of generic medications
  - 5.1.1.2. Increasing patent expiration for blockbuster drugs and the need for cost-effective alternatives
- 5.1.2. Restraints
  - 5.1.2.1. Concerns associated with quality variations in branded generic medications
- 5.1.3. Opportunities
  - 5.1.3.1. Novel bioequivalence studies and efforts by market players to expand branded generics business
- 5.1.4. Challenges
  - 5.1.4.1. Litigation issues and issues related to price erosion of innovator drugs
5.2. Market Segmentation Analysis
- 5.2.1. Product: Significant adoption of value-added branded generics due to their additional advantages
- 5.2.2. Drug Type: High usage of anti-hypertensive for treating high blood pressure
- 5.2.3. Route of Administration: Wide adoption of oral route due to their longer duration of action
- 5.2.4. Indication: Burgeoning utilization of branded generics for gastrointestinal diseases and neurological diseases
- 5.2.5. Distribution Channel: Evolving online distribution channels for branded generics
5.3. Market Trend Analysis
- 5.3.1. Availability of well-structured standards for branded generics in the Americas
- 5.3.2. Supportive government initiatives and growing need for affordable branded generic drugs in the Asia-Pacific region
- 5.3.3. Presence of well-established pharmaceutical companies emphasizing on expanding geographical reach of branded generics in the EMEA region
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework Analysis

6. Branded Generics Market, by Product

6.1. Introduction
6.2. Trade Named Generics
6.3. Value-Added

7. Branded Generics Market, by Drug Type

7.1. Introduction
7.2. Alkylating Agents
7.3. Anti-depressants
7.4. Anti-epileptics
7.5. Anti-hypertensive
7.6. Anti-psychotics
7.7. Antimetabolites
7.8. Hormones
7.9. Lipid Lowering Drugs

8. Branded Generics Market, by Route of Administration

8.1. Introduction
8.2. Oral
8.3. Parenteral
8.4. Topical

9. Branded Generics Market, by Indication

9.1. Introduction
9.2. Acute & Chronic Pain
9.3. Cardiovascular Diseases
9.4. Dermatological Diseases
9.5. Gastrointestinal Diseases
9.6. Neurological Diseases
9.7. Oncology

10. Branded Generics Market, by Distribution Channel

10.1. Introduction
10.2. Offline
10.3. Online

11. Americas Branded Generics Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Branded Generics Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Branded Generics Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
- 14.3.1. Vyvanse Generics Approved by FDA
- 14.3.2. Pharmaceutical Alliance, Generic Pharmaceutical Association Renew Generic Drug Pricing Agreement
- 14.3.3. Amneal Launches Authorized Generic for Xyrem (sodium oxybate) and Receives FDA Approval for Five Complex Generics
- 14.3.4. Ajanta Pharma looks to expand ops in high-growth Asian, African geographies
- 14.3.5. Dr Reddy's Enters Trade Generics Business In Domestic Market
- 14.3.6. Sun Pharma Launches Generic Version of Pfizer's Blockbuster Cancer Drug
- 14.3.7. Zentiva Completes Major Product Acquisition From Tillomed Spain
- 14.3.8. Cipla Launches 'Easylax L',A Sugar-Free Oral Emulsion Laxative For Constipation Relief
- 14.3.9. Procaps Group to Acquire Grupo Somar from Advent International

15. Competitive Portfolio

15.1. Key Company Profiles
15.2. Key Product Portfolio